Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions |
Jul 2020 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis |
Jun 2019 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
Raising the bar for lower-risk myelodysplastic syndromes |
Apr 2023 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience |
Nov 2020 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
Wide Variation in Use and Interpretation of Gene Mutation Profiling Panels Among Health Care Providers of Patients With Myelodysplastic Syndromes: Results of a Large Web-Based Survey |
Jun 2020 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant? |
Nov 2020 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience |
Sep 2020 |
Leukemia & Lymphoma |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents |
Oct 2019 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
Raising the bar for lower-risk myelodysplastic syndromes |
Jun 2023 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML) |
Jul 2020 |
Leukemia |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |